Antibodies in HIV-1 vaccine development and therapy
F Klein, H Mouquet, P Dosenovic, JF Scheid, L Scharf… - Science, 2013 - science.org
Despite 30 years of study, there is no HIV-1 vaccine and, until recently, there was little hope
for a protective immunization. Renewed optimism in this area of research comes in part from …
for a protective immunization. Renewed optimism in this area of research comes in part from …
The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens
R Wyatt, J Sodroski - Science, 1998 - science.org
The human immunodeficiency virus–type 1 (HIV-1) envelope glycoproteins interact with
receptors on the target cell and mediate virus entry by fusing the viral and cell membranes …
receptors on the target cell and mediate virus entry by fusing the viral and cell membranes …
Structure and immune recognition of trimeric pre-fusion HIV-1 Env
The human immunodeficiency virus type 1 (HIV-1) envelope (Env) spike, comprising three
gp120 and three gp41 subunits, is a conformational machine that facilitates HIV-1 entry by …
gp120 and three gp41 subunits, is a conformational machine that facilitates HIV-1 entry by …
Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding
JF Scheid, H Mouquet, B Ueberheide, R Diskin, F Klein… - Science, 2011 - science.org
Passive transfer of broadly neutralizing HIV antibodies can prevent infection, which suggests
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …
that vaccines that elicit such antibodies would be protective. Thus far, however, few broadly …
[HTML][HTML] Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization
Broadly neutralizing antibodies (bNAbs) to HIV-1 can prevent infection and are therefore of
great importance for HIV-1 vaccine design. Notably, bNAbs are highly somatically mutated …
great importance for HIV-1 vaccine design. Notably, bNAbs are highly somatically mutated …
A saposin-lipoprotein nanoparticle system for membrane proteins
J Frauenfeld, R Löving, JP Armache, AFP Sonnen… - Nature …, 2016 - nature.com
A limiting factor in membrane protein research is the ability to solubilize and stabilize such
proteins. Detergents are used most often for solubilizing membrane proteins, but they are …
proteins. Detergents are used most often for solubilizing membrane proteins, but they are …
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
PD Kwong, R Wyatt, J Robinson, RW Sweet, J Sodroski… - Nature, 1998 - nature.com
The entry of human immunodeficiency virus (HIV) into cells requires the sequential
interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and …
interaction of the viral exterior envelope glycoprotein, gp120, with the CD4 glycoprotein and …
Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env
As the sole viral antigen on the HIV-1–virion surface, trimeric Env is a focus of vaccine
efforts. Here we present the structure of the ligand-free HIV-1–Env trimer, fix its conformation …
efforts. Here we present the structure of the ligand-free HIV-1–Env trimer, fix its conformation …
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
JF Scheid, H Mouquet, N Feldhahn, MS Seaman… - Nature, 2009 - nature.com
Antibodies to conserved epitopes on the human immunodeficiency virus (HIV) surface
protein gp140 can protect against infection in non-human primates, and some infected …
protein gp140 can protect against infection in non-human primates, and some infected …
Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers
All previously characterized broadly neutralizing antibodies to the HIV-1 envelope
glycoprotein (Env) target one of four major sites of vulnerability. Here, we define and …
glycoprotein (Env) target one of four major sites of vulnerability. Here, we define and …